Belite Bio (NasdaqCM:BLTE) 2026 Conference Transcript

Summary of Belite Bio Conference Call Company Overview - Company: Belite Bio (NasdaqCM:BLTE) - Product: Tinlarebant, an oral treatment for Stargardt disease Industry Context - Disease: Stargardt disease, an orphan disease affecting the retina, leading to blindness - Prevalence: Approximately 53,000 patients in the U.S., with a global prevalence of about 1 in 7,000, making it one of the top 10 most prevalent inherited diseases [4][8][5] Core Points and Arguments - Mechanism of Action: - Stargardt disease is caused by mutations in the ABCA4 gene, leading to toxic accumulation of all-trans retinal in photoreceptors [12][13] - Tinlarebant works by antagonizing the retinol binding protein (RBP4), reducing retinal delivery to the eye and thereby decreasing toxic accumulation [14][15] - Clinical Trials: - Phase 1B/2 Trial: Showed stabilization of vision over 2 years with a significant reduction in disease progression compared to natural history studies [21][22] - Phase 3 DRAGON Trial: Enrolled 104 patients, demonstrating a 36% reduction in the progression rate of definitely decreased autofluorescence (DDAF) lesions over 2 years, statistically significant with a P value of 0.0033 [27][28] - Secondary endpoint showed a 34% reduction in DAF lesions, also statistically significant [28] - Safety Profile: - Reported 6 serious adverse events, with none related to the drug. Common mild side effects included longer dark adaptation times and temporary visual discoloration [37][40] - Regulatory Plans: - Anticipated FDA submission in the first half of the year, with potential approval in the first quarter of the following year [43][44] - Plans for submissions to other global regulators, including EMA and PMDA in Japan, with a focus on a single trial for multiple regulatory approvals [45][46] Additional Important Information - Market Opportunity: Stargardt disease represents a significant unmet medical need, with no approved treatments currently available [8] - Geographic Variability: Prevalence of ABCA4 mutations varies globally, with the highest rates in populations of African descent [58][60] - Future Studies: Ongoing PHOENIX trial for geographic atrophy, with expectations to outperform existing therapies [66] - Commercial Strategy: Focus on genetic testing to confirm ABCA4 mutations, essential for patient eligibility for Tinlarebant [73] Conclusion Belite Bio is positioned to address a significant unmet need in the treatment of Stargardt disease with its innovative oral therapy, Tinlarebant, backed by promising clinical trial results and a clear regulatory pathway. The company is also preparing for commercialization and expanding its research into related conditions.